Appraisal of amyloidosis imaging practices in the Middle East/North Africa (PYP-MENA)
- PMID: 39045179
- PMCID: PMC11195776
- DOI: 10.1093/ehjimp/qyad025
Appraisal of amyloidosis imaging practices in the Middle East/North Africa (PYP-MENA)
Abstract
Aims: Whereas recommendations to optimize performance and yield of cardiac scintigraphy studies with bone-seeking tracers have been published, little is known about real-world adherence to these best practices, especially outside North America and Europe. Accordingly, we described imaging practices with this modality in a sample of nuclear laboratories in the Middle East/North Africa (MENA) region.
Methods and results: Laboratories performing radionuclide imaging for cardiac amyloidosis in the MENA region were invited to participate in this study to describe installed camera systems, type and dose of bone-avid tracers used, imaging protocols, and criteria used for study interpretation. Out of 19 invited sites, 10 completed the survey (70% government-run; 90% accredited), sites have been involved with amyloid imaging for a median of 49 months (interquartile range 24-60). The median injected dose was 20 mCi (range 10-25), and PYP was used by 90% of sites in this sample. Planar imaging with single photon emission computed tomography (SPECT) reconstruction was performed at all sites, including seven sites that performed SPECT/CT reconstruction. Lastly, only 50% of sites relied on evidence of myocardial uptake by SPECT to confirm the diagnosis of ATTR cardiomyopathy, while the rest relied on visual assessment and heart/contralateral ratio.
Conclusion: This study is the first to describe variation in imaging practices across sites in the MENA region, especially in acquisition protocols and interpretation standards. Eliminating heterogeneities identified by this study will harmonize image interpretation and reporting and will facilitate successful conduct of regional multi-centre studies.
Keywords: SPECT; amyloidosis; bone-avid tracers.
© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.
Conflict of interest statement
Conflict of interest: F.A.B. received research support from Pfizer Gulf FZ LLC. Other authors have nothing to disclose.
Figures
References
-
- Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri Aet al. . Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 2016;133:2404–12. - PubMed
-
- Writing C, Kittleson MM, Ruberg FL, Ambardekar AV, Brannagan TH, Cheng RKet al. . 2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: a report of the American College of Cardiology solution set oversight committee. J Am Coll Cardiol 2023;81:1076–126. - PubMed
-
- Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VAet al. . ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 2 of 2—diagnostic criteria and appropriate utilization. Circ Cardiovasc Imaging 2021;14:e000030. - PubMed
-
- Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VAet al. . ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2—evidence base and standardized methods of imaging. Circ Cardiovasc Imaging 2021;14:e000029. - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous